CytoSorbents, Inc. to Present at the In3 East Medical Device Conference

MONMOUTH JUNCTION, NJ--(Marketwire - June 08, 2010) - CytoSorbents Corporation (OTCBB: CTSO) announced that its Chief Executive Officer and President, Dr. Phillip Chan, will deliver a presentation at the In3 East Medical Device Conference at the Westin Copley Place Hotel in Boston, MA on Thursday, June 10, 2010 at 3:20PM EDT. http://www.in3east.com

“As we work towards CE Mark approval of our flagship product CytoSorb™, we are pleased to discuss the numerous potential clinical applications of our technology with potential investors and strategic partners. CytoSorb™ was uniquely designed to reduce cytokine storm, or the excessive overproduction of cytokines, responsible for the severe inflammation, organ failure and patient death seen in many critical care diseases. Most of these diseases, such as severe sepsis and septic shock, burn and smoke inhalation injury, acute respiratory distress syndrome, acute severe pancreatitis, advanced influenza, trauma and others have limited treatment options and are typically treated with only supportive care therapies and watchful waiting today. CytoSorb represents a new generation of ‘active’ therapies that can potentially reverse or eliminate the underlying damaging cytokine storm, allowing patients to heal and recover faster and to get out of the hospital alive more quickly. We believe the future treatment of critical care diseases revolves around this important concept.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, burn and smoke inhalation injury and rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.